Stocks in Play

Transition Therapeutics Inc.

03:44 PM EST - Transition Therapeutics Inc. : announced that a Phase 2/3 clinical study of neuropsychiatric drug candidate ELND005 did not meet its primary efficacy endpoint. Transition Therapeutics Inc.
shares T.TTH are trading down $7.89 at $3.02.